Survival Impact of Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer

• DOI: 10.1007/s43032-024-01687-5
• Publication Date: 2024-08-27T17:03:00Z
• Authors: María Alonso-Espías; Mikel Gorostidi; Virginia García-P...; Myriam Gracia; María Dolores Die...; Jaime Siegrist; Ignacio Zapardiel; Alicia Hernández
• Keywords: Adult; Sentinel Lymph Node Biopsy; Lymphatic Metastasis; Humans; Uterine Cervical Neoplasms; Lymph Node Excision; Female; Middle Aged; Retrospective Studies; Neoplasm Staging; Aged; Pelvis

To assess whether there were statistically significant differences in terms of overall survival (OS) and progression-free survival (PFS) between pelvic lymphadenectomy (PL) and sentinel lymph node biopsy (SLNB) alone as a nodal assessment method in patients with early-stage cervical cancer (IA1 with ILV to IB2 or IIA1 of the FIGO 2018 classification). A retrospective study was conducted among patients with early-stage cervical cancer who underwent radical surgery with pelvic lymph node assessment at La Paz University Hospital between 2005 and 2022. For nodal staging, either PL, SLNB + PL, or exclusive SLNB were performed, depending on the time period. Kaplan-Meier survival curves were compared between the PL and SLNB groups. Predictors of bilateral sentinel lymph node (SLN) detection were identified with Cox proportional hazard models. Among the 128 patients included, PL ± SLNB was performed in 79 (61.7%) patients and exclusive SLNB in 49 (38.3%) patients. There was no difference between PL and SLNB in OS (log-rank 0.0730) or PFS (log-rank 0.0189). Lower limb lymphedema (LLL) was significantly lower in the SLNB group (p = 0.001). Pelvic nodal assessment with SLNB alone did not worsen survival rates compared with the standard PL in patients with early-stage cervical cancer, and it is associated with a lower rate of LLL.